Dersimelagon, a novel oral melanocortin 1 receptor agonist, demonstrates disease-modifying effects in preclinical models of systemic sclerosis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1478-6362
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Dersimelagon, a novel oral melanocortin 1 receptor agonist, demonstrates disease-modifying effects in preclinical models of systemic sclerosis ; volume:24 ; number:1 ; day:1 ; month:9 ; year:2022 ; pages:1-17 ; date:12.2022
Arthritis Research & Therapy ; 24, Heft 1 (1.9.2022), 1-17, 12.2022
- Urheber
-
Kondo, Masahiro
Suzuki, Tsuyoshi
Kawano, Yuko
Kojima, Shinji
Miyashiro, Masahiko
Matsumoto, Atsuhiro
Kania, Gabriela
Błyszczuk, Przemysław
Ross, Rebecca L.
Mulipa, Panji
Galdo, Francesco Del
Zhang, Yun
Distler, Jörg H. W.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13075-022-02899-3
- URN
-
urn:nbn:de:101:1-2022111909082881301156
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:26 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Kondo, Masahiro
- Suzuki, Tsuyoshi
- Kawano, Yuko
- Kojima, Shinji
- Miyashiro, Masahiko
- Matsumoto, Atsuhiro
- Kania, Gabriela
- Błyszczuk, Przemysław
- Ross, Rebecca L.
- Mulipa, Panji
- Galdo, Francesco Del
- Zhang, Yun
- Distler, Jörg H. W.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Fibroblast activation protein inhibitor PET/CT as an emerging diagnostic modality in interstitial lung disease and other fibrotic conditions
Pharmacological inhibition of porcupine as monotherapy or in combination with ruxolitinib, ibrutinib or belumosudil in experimental sclerodermatous chronic graft-versus-host disease
Combined inhibition of morphogen pathways demonstrates additive antifibrotic effects and improved tolerability
Current Disease-Modifying Therapies in Multiple Sclerosis
Disease-modifying treatments in Alzheimer’s disease
Disease-modifying effects of metabolic perturbations in ALS/FTLD
Lithium as a disease-modifying agent for prion diseases
Current experimental disease-modifying therapeutics for multiple system atrophy
Jellyfish mucin may have potential disease-modifying effects on osteoarthritis
Current Symptomatic and Disease-Modifying Treatments in Multiple System Atrophy
Disease‐modifying effects of ganglioside GM1 in Huntington's disease models
Disease-modifying effects of ranibizumab for central retinal vein occlusion
Fibroblast activation protein inhibitor PET/CT as an emerging diagnostic modality in interstitial lung disease and other fibrotic conditions
Pharmacological inhibition of porcupine as monotherapy or in combination with ruxolitinib, ibrutinib or belumosudil in experimental sclerodermatous chronic graft-versus-host disease
Combined inhibition of morphogen pathways demonstrates additive antifibrotic effects and improved tolerability
Current Disease-Modifying Therapies in Multiple Sclerosis
Disease-modifying treatments in Alzheimer’s disease
Disease-modifying effects of metabolic perturbations in ALS/FTLD
Lithium as a disease-modifying agent for prion diseases
Current experimental disease-modifying therapeutics for multiple system atrophy
Jellyfish mucin may have potential disease-modifying effects on osteoarthritis
Current Symptomatic and Disease-Modifying Treatments in Multiple System Atrophy
Disease‐modifying effects of ganglioside GM1 in Huntington's disease models
Disease-modifying effects of ranibizumab for central retinal vein occlusion
Fibroblast activation protein inhibitor PET/CT as an emerging diagnostic modality in interstitial lung disease and other fibrotic conditions
Pharmacological inhibition of porcupine as monotherapy or in combination with ruxolitinib, ibrutinib or belumosudil in experimental sclerodermatous chronic graft-versus-host disease
Combined inhibition of morphogen pathways demonstrates additive antifibrotic effects and improved tolerability
Current Disease-Modifying Therapies in Multiple Sclerosis
Disease-modifying treatments in Alzheimer’s disease
Disease-modifying effects of metabolic perturbations in ALS/FTLD
Lithium as a disease-modifying agent for prion diseases
Current experimental disease-modifying therapeutics for multiple system atrophy
Jellyfish mucin may have potential disease-modifying effects on osteoarthritis
Current Symptomatic and Disease-Modifying Treatments in Multiple System Atrophy
Disease‐modifying effects of ganglioside GM1 in Huntington's disease models